US BioThrax scale-up contract could bring Emergent up to $107 million
This article was originally published in Scrip
Executive Summary
Emergent BioSolutions has signed a contract worth up to $107 million with the US Biomedical Advanced Research and Development Authority (BARDA) to scale up manufacturing of its anthrax vaccine BioThrax, the only vaccine so far licensed by the US FDA for the prevention of anthrax infection.